Pfizer Inc
NYSE: PFE
$28.94
-$0.29 (-1.0%)
Real Time Data Delayed 15 Min.
PFE Articles
Wikimedia CommonsBefore the market opens on Tuesday morning, Pfizer Inc. (NYSE: PFE) is scheduled to report second-quarter results. The company is expected to post earnings per share (EPS) of $0.52...
Published:
Last Updated:
ThinkstockThe short interest data have been released for the July 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market...
Published:
Last Updated:
ThinkstockPharmaceutical and Biotech investors are about to get a real show for earnings this week. Big Pharma will bring earnings from Dow Jones Industrial Average companies Merck & Co. Inc....
Published:
A new report from Jefferies updates the firm's top global pharmaceutical stocks to buy, and these picks make sense for investors now.
Published:
The June 30 short interest data have been compared with the previous figures, and across the selected pharmaceutical stocks, short interest decreased.
Published:
thinkstockJuly 9, 2015: Markets opened higher on Thursday and that’s when the major indexes posted their daily highs. New claims for unemployment benefits remain at close to the averages for full...
Published:
Last Updated:
A new report from UBS highlights three stocks that the firm likes best now. Not only do they all pay a solid dividend and have a good potential for growth, they all could help cushion a portfolio...
Published:
thinkstockJuly 7, 2015: Markets opened slightly higher on Tuesday but a reversal took just moments to set in and U.S. equities traded mostly lower for the remainder of the day. Commodities of all...
Published:
Last Updated:
How much are big pharmaceutical companies really spending to get their drugs out there in the public eye?
Published:
The June 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
Published:
The May 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest is down.
Published:
Credit Suisse has updated its autoimmune market model and it sees implications for all of the large cap U.S. pharmaceutical companies in its coverage.
Published:
This coming week is likely to be a serious one in the fight against cholesterol. FDA panels are evaluating more than just one drug candidate.
Published:
Investors looking to move down in volatility but stay fully invested may want to consider moving capital to any of these three value stocks.
Published:
The short interest data has been released for the May 15 settlement date and for the selected pharmaceutical stocks, short interest is mixed.
Published: